MedTrace Logo

RElapse After Allograft: Link Between LoCus of Control and QualiTy of Life

NCT05258929 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2024-03-04

No results posted yet for this study

Summary

Allogeneic hematopoietic transplantation (AlloHCT) is a robust therapeutic that is used as a consolidation strategy in a number of haematological cancers. It provides durable responses as compared to chemotherapy alone. Despite the potential of the graft-versus-tumor effect that is driven by AlloHCT, relapse after AlloHCT remains common. Yet, the psychological impact of relapse after allograft is poorly appreciated.

Conditions

  • Allograft
  • Post-allograft Relapse

Interventions

OTHER

Data collection (Prior and planned treatments, allograft)

MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Denis Guyotat, PhD · CHU de Saint-Etienne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-06-04
Completion
2022-06-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05258929 on ClinicalTrials.gov